Core Viewpoint - Haohai Biological Technology (688366.SH) plans to acquire approximately 8.466 million shares of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. (Ruiji Bio), representing 19.8% of Ruiji Bio's total share capital, for about 38.35 million yuan, raising concerns among investors due to the absence of performance commitments or earn-out arrangements [1][4]. Group 1: Acquisition Details - The acquisition is aimed at enhancing Haohai's product portfolio and business resilience, as well as laying the groundwork for the development of innovative material products [3]. - The total valuation of Ruiji Bio in this transaction is approximately 194 million yuan, which reflects a significant premium over its net asset value of several tens of millions [3]. - Haohai will become the sixth largest shareholder of Ruiji Bio after the acquisition, with its major shareholder, You Jie, already holding a significant stake in Ruiji Bio [5][6]. Group 2: Financial Performance of Ruiji Bio - Ruiji Bio has been operating at a loss, with a net profit of approximately -1.18 million yuan in 2024 and -1.13 million yuan in the first three quarters of 2025, indicating a trend of declining financial performance [4][8]. - The company's total assets were about 98.89 million yuan in 2024, with total liabilities of approximately 11.20 million yuan, leading to a net asset value of around 87.69 million yuan [4]. - The revenue for Ruiji Bio was approximately 46.36 million yuan in 2024, with a similar revenue figure of about 46.09 million yuan reported for the first three quarters of 2025, suggesting stagnation in sales [4]. Group 3: Market Context and Strategic Implications - The acquisition allows Haohai to enter the high-value medical device market, specifically in the field of biological amniotic membranes, which are used in orthopedic and ophthalmic applications [7]. - Haohai's recent acquisition of the remaining 20% stake in Shenzhen New Industry Ophthalmology Technology Co., Ltd. indicates a strategic focus on enhancing its presence in the ophthalmic high-value consumables sector [7]. - The company has faced declining revenues across its core business segments, with a reported 7.12% decrease in revenue year-on-year for the first half of the year, driven by factors such as insufficient domestic demand and price competition [8].

Core Viewpoint - Haohai Biological Technology (昊海生科) plans to invest in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. (瑞济生物) to enter the high-value biological amniotic membrane market despite experiencing a decline in revenue and net profit [1][4]. Group 1: Investment Details - Haohai will acquire a total of 19.8% of Ruiji Biological's shares through a framework agreement, paying 38.35 million yuan and 4.76 million yuan in three phases for 8.4661 million shares and 1.0499 million shares respectively [1][3]. - The transaction price is set at 4.53 yuan per share, based on the market price before Ruiji Biological's delisting from the National Equities Exchange and Quotations [3][9]. Group 2: Company Background - Ruiji Biological, established in 2002, specializes in the production and sale of biological amniotic membranes, which are classified as Class III medical devices used in orthopedic and ophthalmic fields [1][3]. - Haohai aims to enhance its product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors by obtaining distribution rights for Ruiji's products in China [3][9]. Group 3: Financial Performance - Ruiji Biological reported revenues of approximately 46.36 million yuan and 46.09 million yuan for 2024 and the first three quarters of 2025, respectively, with net losses of 11.77 million yuan and 11.29 million yuan [4][10]. - Haohai's revenue for the first three quarters of this year was about 1.899 billion yuan, a year-on-year decrease of 8.47%, with a corresponding net profit of approximately 305 million yuan, down 10.63% year-on-year [4][10]. Group 4: Risks and Challenges - The transaction does not include performance commitments or earn-out arrangements, which means there are risks associated with potential underperformance of Ruiji Biological [4][10]. - Market conditions and sales channels may affect the sales performance of the acquired products, posing risks of reduced investment returns and failure to achieve acquisition objectives [5][10].

Core Viewpoint - Haohai Biological Technology (688366) plans to enter the high-value biological amniotic membrane market despite a decline in revenue and net profit, through acquiring a 19.8% stake in Ruijibio [1][3][5]. Group 1: Company Acquisition Details - Haohai Biological signed a share transfer framework agreement to acquire shares from Ruijibio's existing shareholders for a total of approximately 43.91 million yuan [1]. - The acquisition price is set at 4.53 yuan per share, based on the market price before Ruijibio's delisting from the National Equities Exchange and Quotations [3]. - Ruijibio specializes in producing and selling biological amniotic membranes, which are classified as Class III medical devices used in orthopedic and ophthalmic fields [1][3]. Group 2: Financial Performance - Ruijibio reported revenues of approximately 46.36 million yuan and 46.09 million yuan for 2024 and the first three quarters of 2025, respectively, with net losses of 11.77 million yuan and 11.29 million yuan [4]. - Haohai Biological's revenue for the first three quarters of this year was approximately 1.899 billion yuan, a year-on-year decrease of 8.47%, while net profit was about 305 million yuan, down 10.63% year-on-year [5]. Group 3: Strategic Implications - The investment in Ruijibio is expected to enhance Haohai Biological's product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors [3]. - The biological amniotic membrane materials possess human-derived biological characteristics, providing a significant technological and material foundation for research and development in regenerative medicine and tissue engineering [3].

Core Viewpoint - The company Haohai Biological Technology (688366.SH) plans to acquire a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for RMB 38.35 million, enhancing its presence in the high-value medical device sector focused on biological amniotic membranes [1] Group 1: Company Acquisition - Haohai Biological Technology will use its own funds to acquire 8.4661 million shares from shareholders Miao Jiuchang and Miao Chunyu [1] - The acquisition allows Haohai to gain distribution rights for Ruiji's products within China, thereby expanding its product portfolio in the ophthalmology and orthopedics fields [1] Group 2: Business Overview of Ruiji - Ruiji Biological was established in 2002 and specializes in the production and sale of biological amniotic membranes, which are classified as Class III medical devices [1] - The main products include convex and concave amniotic membranes, biological orthopedic amniotic membranes, and wet biological amniotic membranes, used primarily in orthopedic and ophthalmic applications [1] Group 3: Strategic Implications - The acquisition is expected to provide important technical and material foundations for Haohai's research and development in regenerative medicine and tissue engineering [1] - The human-derived biological characteristics of the amniotic materials are anticipated to drive innovation and technological upgrades in subsequent product offerings [1]

Core Viewpoint - Company Haohai Biological Technology (688366.SH) plans to acquire 8.4661 million shares of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for RMB 38.3515 million, representing 19.8% of Ruiji's total share capital [1] Group 1: Company Overview - Jiangxi Ruiji was established in 2002 and specializes in the production and sales of biological amniotic membranes [1] - The main products include convex and concave amniotic membrane products, biological orthopedic amniotic membrane products, and wet biological amniotic membrane products, classified as Class III medical devices [1] Group 2: Market and Product Applications - The products are primarily used in orthopedic and ophthalmic fields, including tendon repair, treatment of ocular burns and injuries, and support after lacrimal duct obstruction [1] - The acquisition allows the company to gain distribution rights for Ruiji's products in China, entering the high-value medical device sector of biological amniotic membranes [1] Group 3: Strategic Implications - The acquisition is expected to effectively supplement the company's existing product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors [1] - Ruiji's amniotic membrane materials possess human-derived biological characteristics, providing essential technical and material foundations for the company's research and development in regenerative medicine and tissue engineering [1] - This move is anticipated to drive subsequent product innovation and technological upgrades for the company [1]

Core Viewpoint - Haohai Biological Technology (688366) plans to acquire 8.4661 million shares of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for 38.3515 million yuan, representing 19.8% of Ruiji's total share capital [1] Group 1: Company Acquisition - The acquisition will be funded by the company's own capital [1] - The target company, Ruiji Biological, was established in 2002 and specializes in the production and sales of biological amniotic membranes [1] - The main products include convex and concave amniotic membrane products, biological orthopedic amniotic membrane products, and wet biological amniotic membrane products, classified as Class III medical devices [1] Group 2: Market and Product Applications - The products are primarily used in orthopedic and ophthalmic fields, including tendon repair, treatment of ocular burns and injuries, and support after lacrimal duct obstruction procedures [1] - By investing in Ruiji Biological, the company aims to gain distribution rights for Ruiji's products in China, effectively entering the high-value medical device market of biological amniotic membranes [1] - This acquisition will enhance the company's existing product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors [1]